Dear John,

Today, the Fraser Institute released a new study, Biologics and Biosimilars: A Primer [[link removed]].

This study finds that Canadian patient access to potentially life-saving biologic medicines is comparatively limited because Canada’s protection of intellectual property in the life sciences—including biology and biochemistry—lags behind other industrialized countries.

Below is the news release and accompanying infographic. Please share with your colleagues and friends.

Best,

Niels

Niels Veldhuis | President

The Fraser Institute

1770 Burrard Street, 4th Floor, Vancouver, BC V6J 3G7

Canada’s comparatively weak intellectual property protections limit access to life-saving drugs

VANCOUVER—Because Canada’s protection of intellectual property in the life sciences—including biology and biochemistry—lags behind other industrialized countries, Canadian patient access to potentially life-saving biologic medicines is comparatively limited, finds a new study released today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank.

“Cutting-edge biologic drugs are treating previously untreatable conditions, often with fewer adverse effects, improving the health of patients and saving lives worldwide,” said Kristina Acri, associate professor of economics at Colorado College, senior fellow at the Fraser Institute and author of Biologics and Biosimilars: A Primer [[link removed]].

According to the study, as of December 2018 (the latest month of comparable data), Canada has approved only 10 “biosimilars,” which are versions of biologic drugs, compared to 15 in the United States, 20 in Australia and 62 in the European Union.

Biologic drugs are produced from (or contain elements of) living organisms. They are more complicated—and more expensive—to develop, produce, distribute and dispense than other medicines.

Subsequently, the ability of drug companies to protect their intellectual property—for example, through data exclusivity, which essentially prevents competing firms from producing generic versions of the drugs for a period of time—is essential for incentivizing the development of biologics, particularly because biopharmaceutical innovations are easily copied and sold by competitors.

Unfortunately, Canada’s current intellectual property laws are weak compared to laws in other jurisdictions including the U.S. and EU. For example, Canada has one of the shortest terms of data exclusivity for pre-clinical and clinical trials.

“If Canadian policymakers want to improve access to state-of-the-art drugs in Canada, they must strengthen protections for intellectual property,” Acri said.

STAY UP TO DATE

SUPPORT THE FRASER INSTITUTE

The Fraser Institute has been ranked the #1 think tank in Canada, and the 14th best think tank out of more than 8,200 around the world! We keep Canadians – and decision-makers! – informed.

But we are only as strong as our supporters. We do not accept government grants or payments for research - we depend on individuals like you to continue our good work! We are a charity - your donation entitles you to a generous tax credit at tax time!

Contact Us [[link removed]] Privacy Policy [[link removed]] Unsubscribe [link removed] The Fraser Institute's mission is to improve the quality of life for Canadians, their families and future generations by studying, measuring and broadly communicating the effects of government policies, entrepreneurship and choice on their well-being. Email is one of the best tools we have to accomplish these goals. If you no longer wish to receive e-mail updates from us, click here to unsubscribe [link removed].

Fraser Institute 4th Floor, 1770 Burrard Street Vancouver, BC V6J 3G7